Esperion Therapeutics, Inc.
ESPREsperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Drugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
Ezetimibe
Hypercholesterolemia
Bempedoic Acid
Hyperlipidemias
Bempedoic acid 180 mg tablet
Cardiovascular Diseases
ETC-1002
Hyperlipidemia
bempedoic acid 180mg
Hypercholesterolemia
Ezetimibe 10mg
Hypercholesterolemia
Atorvastatin
Hypercholesterolemia
Bempedoic acid + Ezetimibe FDC Oral Tablet
Diabetes
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ezetimibe | Phase 3 | Hypercholesterolemia | - | - |
Bempedoic Acid | Phase 3 | Hyperlipidemias | - | - |
Bempedoic acid 180 mg tablet | Phase 3 | Cardiovascular Diseases | - | - |
ETC-1002 | Phase 3 | Hyperlipidemia | - | - |
bempedoic acid 180mg | Phase 2 | Hypercholesterolemia | - | - |
Ezetimibe 10mg | Phase 2 | Hypercholesterolemia | - | - |
Atorvastatin | Phase 2 | Hypercholesterolemia | - | - |
Bempedoic acid + Ezetimibe FDC Oral Tablet | Phase 2 | Diabetes | - | - |